

Short Report

**DNA Methylation Analysis of the COVID-19 host cell receptor, Angiotensin I  
Converting Enzyme 2 gene (ACE2) in the Respiratory System Reveal Age and  
Gender Differences**

**AUTHORS:**

<sup>1</sup>Michael J. Corley and <sup>1</sup>Lishomwa C. Ndhlovu\*

**AFFILIATION:**

<sup>1</sup>Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical  
College, New York, NY, USA.

*\*Corresponding Author*

**Correspondence:**

Lishomwa C. Ndhlovu MD, PhD,  
Division of Infectious Diseases, Department of Medicine,  
Weill Cornell Medical College,  
413E 69<sup>th</sup> St, New York, NY, USA.  
Email: lndhlovu@med.cornell.edu

**Keywords:**

Wuhan 2019-nCoV, ACE2, DNA methylation, epigenetics, profiling, lung tissue, age,  
gender, COVID-19, coronavirus

**CONFLICT OF INTEREST:** Authors declare no conflict of interest.

**ABSTRACT:**

**Background:** Coronavirus disease 2019 (COVID-19) has emerged as a global threat to human health and disease risk increases with advancing age. The regulation of the *ACE2* gene that codes for COVID-19 host receptor ACE2 has been shown to be under epigenetic regulation. Here, we examined whether intensive DNA methylation profiling of the *ACE2* gene differed by human host tissue and cell type, gender, and age.

**Results:** Accessing four public datasets, we observed unique human cell-type-specific *ACE2* DNA methylation patterns. In human lung tissues, gender differences in DNA methylation at 2 sites related to the *ACE2* gene were identified. Further, in freshly isolated airway epithelial cells, DNA methylation near the transcription start site of the *ACE2* gene associated with biological age.

**Conclusion:** Epigenetic profiling of host tissue may permit discovery of age and gender-related potential risk factors for COVID-19. How perturbations in *ACE2* methylation relate to clinical severity across the ages and gender needs to be determined to guide screening tools and potential epigenetic modification targeting to alleviate COVID-19 morbidity in the elderly.

## INTRODUCTION:

An outbreak of COVID-2019 emerged in Wuhan, China in December 2019 as a highly contagious coronavirus[1] capable of human infection and transmission [2,3], and possible mortality following infection similar to the SARS coronavirus [4]. As of March 11, 2020, COVID-19 case fatality rate globally is estimated by the WHO at 3.48% based on 109,578 confirmed cases and 3,809 deaths and this infection has evolved into a pandemic[5]. In the United States (US) as of March 16, 2020 a total of 3,487 cases have been reported with total 68 deaths across 49 states including the District of Columbia as a multipronged surveillance and containment strategy has been initiated across the country with a reported mean incubation period of 6.4 days[6]. Recent analysis of epidemiological data suggests that as many as 86% of all COVID-19 infections are undocumented and are contributing to the rapid worldwide increase in cases[7].

Clinical research has described COVID-19 as an acute respiratory tract infection with varied severity of symptoms including fever onset by dry cough. Clinical treatment of patients infect with COVID-19 has evolving management guidelines of the disease[2,3,8,9]. Epidemiology research has documented the spread and fatality rates for the virus[10], virology research has characterized the genomic features and evolution of COVID-2019[11–14], and vaccine research has started development and testing of candidate vaccines[15,16]. The global spread of the virus and diversity of human host capable of infection highlight the importance of understanding host biological differences related to COVID-2019. There remain numerous key questions on biological factors that contribute to varying host responses and clinical outcomes. Data from other human

pathogenic coronaviruses SARS-CoV and MERS-CoV[17–19] has provided some insight into potential biological factors underlying varied host responses and clinical outcomes. Sex-based differences in susceptibility to SARS-CoV infection have been reported in mice that parallel those observed in patients and this work identified estrogen receptor signaling as critical for protection in females[20]. Initial reports suggest sex and age-related differences in COVID-2019 that warrant further investigation[17,21]. Research is needed to understand specific sex-related biological features that underlie clinical severity and treatment strategies for COVID-2019 in men and women.

Structural analyses have revealed that receptor angiotensin-converting enzyme 2 (ACE2) as a host receptor permitting cell entry and viral infectivity for COVID-2019[22,23]. Notably, ACE2 was also identified as a host receptor for other coronaviruses including SARS-CoV and NL63[24]. ACE2 has been well studied as a central regulator of blood pressure in the renin-angiotensin-aldosterone system[25]. Studies have shown that ACE2 protein and mRNA expression occurs in a variety of human tissues including lung, liver, stomach, ileum, colon, and kidney[26,27]. Recent single cell analyses of normal human tissues have shown that *ACE2* is expressed in cells of the respiratory and digestive system suggesting the lung and gut body compartments as routes for COVID-2019 infection, viral replication, and viral shedding[28–30]. Epigenetics research has suggested that the *ACE2* gene that codes for ACE2 may be transcriptionally regulated by DNA methylation[31], which is a covalent chemical modification of host DNA. Moreover, *ACE2* is located on the X chromosome[32] raising the possibility of gender differences in susceptibility and progression of COVID-


2019[17,19,21]. Thus far, no study has examined the epigenetic landscape of *ACE2* and whether it differs by age or gender.

In this study, we accessed four available genome-wide DNA methylation human datasets to examine whether DNA methylation profiling related to the *ACE2* gene differed by host tissue/cell type, sex, and varied by biological age to begin to understand and address the hypothesis of whether epigenetic footprints related to *ACE2* impact susceptibility risk for COVID-19, disease progression, mortality and morbidity.

## **RESULTS AND DISCUSSION:**

We examined evidence for varied DNA methylation patterns related to the *ACE2* gene in human lung, gut, liver, pancreas, brain, and blood by accessing a subset of available raw genome-wide DNA methylation array data[33] (GEO accession: GSE122126). We analyzed the Illumina MethylationEPIC DNA methylation data using the Chip Analysis Methylation Pipeline[34] and observed that DNA methylation levels at loci related to the *ACE2* gene of various human tissue cell types showed that DNA methylation was varied across tissue cell types (**Fig. 1**). Notably, DNA methylation across three CpGs (cg04013915, cg08559914, cg03536816) assayed for the *ACE2* gene was lowest in lung epithelial cells compared to the other tissue cell types (**Fig. 1**), suggesting transcription and expression to be highest in the lung/respiratory system compartment which supports emerging single cell RNA-seq analyses of normal human lung/respiratory system datasets[28–30]. Average total DNA methylation at all probes

related to the *ACE2* gene was hypermethylated in cortical neurons and leukocytes compared to other cell types examined, suggesting excluded *ACE2* transcription and protein expression in these cell types reported previously [26,27].



**Figure 1. Distinct tissue cell type DNA methylation profile related to *ACE2*.** DNA methylation of 11 CpGs surveyed by the Illumina Infinium MethylationEPIC array related to *ACE2* gene from lung epithelial, hepatocytes, colon epithelial, pancreatic duct, pancreatic beta, pancreatic acinar, cortical neurons, and leukocytes is shown from GEO accession: GSE122126. DNA methylation level is shown for each CpG as ranging from 0 to 1.0 (methylation normalized beta-value).


Since lung epithelial cells were observed to have a hypomethylation at the *ACE2* gene, we sought to further examine DNA methylation levels in human lung tissues. We accessed available genome-wide DNA methylation Illumina HumanMethylation450 data from human lung tissues containing samples from both males and females and including data from smokers and patients with chronic obstructive pulmonary disease[35]. Analysis

of DNA methylation at two CpG sites related to the *ACE2* gene showed that females were significantly hypomethylated compared to males ( $P = 0.0001$ ) (**Fig. 2**).


Additionally, DNA methylation trended towards being hyper-methylation in lung disease conditions including smoking and COPD compared to normal lung although not statistically significant due to limited sample size ( $P = 0.18$ ). Notably, the *ACE2* gene is located on the X chromosome raising the possibility of methylation differences due to X chromosome activation[36]. Of note, the genome-wide Illumina HumanMethylation450 array measures DNA methylation in both X chromosomes of the females. These initial gender-associated differences in DNA methylation related to the *ACE2* gene in lung tissues warrant further investigation, especially in the context of *ACE2* gene and protein expression and COVID-19 severity. To examine the variability in DNA methylation levels related to *ACE2* in males and females, we accessed Illumina HumanMethylation450 DNA methylation data from 244 fresh human lung tissues[37]. We observed that DNA methylation at a CpG in the dataset related to the *ACE2* gene showed a large degree of variability in both men and women suggesting DNA methylation of *ACE2* varies by individual (**Fig. 3**). Of note, this dataset did not have metadata for age and the differences in DNA methylation related to *ACE2* may be reflective of cell type differences in the lung tissues.

These gender-related differences in *ACE2* DNA methylation observed in the respiratory system support findings that indicate that Angiotensin II metabolism varies by gender and may relate to hormonal differences or genetic differences in chromosome dosage[38]. Our DNA methylation data contrast a recent preprint study that reanalyzed five bulk transcriptome datasets of normal lung tissue and two single cell transcriptome

dataset reported no significant differences in *ACE2* between racial groups, age groups, or gender groups[30]. A major limitation of this study was the sample size and multiple comparisons as well as the focus only on *ACE2* transcription. Notably, the *ACE2* transcription preprint study did report higher expression in Asian current smokers compared to non-smokers supporting our observations of a trend in differences in *ACE2* in lung of male smokers. Smoking dramatically impacts the epigenome and will be a key environmental factor to examine in future epigenetic studies of COVID-19[39,40]. Additional research will need to determine whether protein, gene transcription, or epigenetic landscape of *ACE2* is most relevant to COVID-19 infection risk, disease severity, and transmission.




**Figure 2. DNA methylation at two CpG loci related to *ACE2* gene in human lung tissues of smokers and patients with chronic obstructive pulmonary disease (COPD) by gender from GEO accession: GSM2430978. DNA methylation level is shown for each CpG as ranging from 0 to 1.0 (methylation normalized beta-value).**



**Figure 3. DNA methylation variability related to *ACE2* gene in human lung tissues men and women from GEO accession: GSE52401. DNA methylation level is shown line at median with minimum and maximum (methylation normalized beta-value).**


Next, based on epigenetics work showing DNA methylation sites associated with longitudinal lung function decline and aging in humans[41] and given reports out China highlighting the increased risk of COVID-19 severity in older individuals[3] due to a myriad of potential biological factors, we sought to test our hypothesis that DNA methylation related to the *ACE2* gene associated with age in the respiratory system. Therefore, we obtained genome-wide DNA methylation array data from freshly isolated airway epithelial cells of non-asthmatics of varying biological ages and evaluated whether the methylation levels for CpGs related to the *ACE2* gene related to biological age. We found that one CpG (cg08559914) near the transcription start site of the *ACE2* gene significantly associated with biological age in airway epithelial cells ( $r=-0.59$ ,  $P=0.001$ ; **Fig. 4**). This finding was notable given that the Illumina DNA methylation array data analyzed for *ACE2* gene did not measure DNA methylation at every CpG but only 7 CpG sites. Whole genome bisulfite sequencing will provide further insight into whether there are additional DNA methylation sites related to the *ACE2* gene that dynamically

associate with age. These findings suggest and age-related change in the epigenetic regulation of *ACE2* in the respiratory system exist and are relevant to studies of *ACE2* and COVID-19 in elderly. Our findings complement emerging single cell transcriptional profiling data that is suggesting that nasal goblet/secretory and ciliated cells of the respiratory system show the highest *ACE2* transcription[29] and highlight the need for age-related single transcriptomic and epigenetic profiling studies of the respiratory system in COVID-19. Whether this dramatic relationship between *ACE2* DNA methylation and aging is mediated by other aging-related complications or is a major factor contributing to older individuals being more susceptible or younger individuals being less susceptible to severe COVID-19 infection needs to be studied.



**Figure 4. DNA methylation at a CpG loci in the TSS200 region related to *ACE2* gene in airway epithelial cells harvested via bronchial brushing from non-asthmatic females from GEO accession: GSE85566) significantly associates with biological age ( $r = -0.59$ ,  $P = 0.001$ )**

We also examined public available data from ENCODE for RNA-Seq from human Lung donors including a 3 year old male, 30 year old female, and fetal samples[42,43]. Interestingly, high levels of transcription were observed in young male lung compared to fetal lung and female lung (**Fig. 5**). Moreover, we observed in a publicly available ENCODE Hi-C dataset for IMR90 cells[42] used to examine genome-wide chromatin organization that chromatin interaction contacts occurred near the site we observed DNA methylation differences for the *ACE2* gene, suggesting a potential spatiotemporal gene expression program for *ACE2* mediated by DNA methylation. Additional single cell 3D chromatin research in normal respiratory system and during COVID-19 infection will need to examine whether a promoter-enhancer interaction for *ACE2* exist and modulates differential host and respiratory system cell type expression patterns.



**Figure 5. Scaled gene view from WashU Epigenome Browser[43] of *ACE2* human gene. *ACE2* gene track showed in purple from gencodeV29. RNA-Seq tracks from human lung and fetal lung obtained from ENCODE[42] shown in blue. CpG methylation data of the seven 450K array probes over the *ACE2* gene shown as blue lines at each CpG. Hi-C genome-wide chromosome organization data from IMR90 cells shown with view of interaction contacts in purple 20kb resolution.**

In this study, we observed DNA methylation levels associated with *ACE2* gene varied by tissue type, differed by gender and disease state in lung, and associated with biological age in airway epithelial cells. Notably, the significant relationship between DNA methylation of *ACE2* and biological age suggest age-dependent differences in host response may be mediated by the dysregulation of *ACE2* and increased expression of *ACE2* with aging. While our DNA methylation findings related to the *ACE2* gene are compelling, *ACE2* is dynamically regulated in the body transcriptionally, posttranscriptionally, and posttranslationally[44]. Further work will need to determine whether other pre-existing health conditions such as diabetes and hypertension or medications being taken such as ACE inhibitors and angiotensin II type-I receptor blockers lead the dysregulation of *ACE2* and increased severe outcomes of COVID-19 infection[45]. This notion has recently received attention and controversy and deserves further study[46]. Additionally, the use of ACE inhibitors as therapeutics to prevent COVID-19 viral entry also warrants further investigation[47].

In summary, our work focused on studying available epigenetic DNA methylation data to begin to characterize and focus on the tissue/cell type specific epigenetic landscape of the COVID-19 host receptor gene *ACE2*. Future work should examine varying host epigenetic landscapes during COVID-19 infection to understand whether COVID-2019 antagonizes antigen presentation through epigenetic modulation similar to MERS-CoV [48]. This information will be vital to vaccine development and epigenetic therapeutics for COVID-19. Another compelling question is whether the DNA

methylation profile of *ACE2* in COVID-19 viral replication body sites associates with “super spreaders” and enhanced transmissivity.

## **METHODS**

### **Public dataset acquisition and processing.**

Public DNA methylation datasets were downloaded from the Gene Expression Omnibus website. DNA methylation data for human isolated cell populations from tissues was obtained from (GEO: GSE122126). DNA methylation data for airway epithelial cells used to examine the relationship with age was obtained from (GEO: GSE85568). DNA methylation data for lungs tissues of smokers and patients with COPD by gender was obtained from (GEO: GSE92511). DNA methylation data for normal lungs tissues by gender was obtained from (GEO: GSE52401). RAW IDAT files were loaded into ChAMP pipeline, preprocessed, and normalized[34]. We loaded RNA-Seq and Hi-C datasets from the ENCODE portal[49] (<https://www.encodeproject.org/>) into the WashU Epigenome Browser. Statistical tests were conducted in Graphpad Prism 8 for DNA methylation data related to the *ACE2* gene.

## CONFLICT OF INTEREST

Authors declare no conflict of interest.

## ACKNOWLEDGEMENTS

We would like to acknowledge the authors that deposited raw DNA methylation data for analysis relevant to *ACE2*. Public access to all formats of data relevant to COVID-19 will aid in overcoming the pandemic.

## REFERENCES

1. Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier HJ, Bickerton E, Britton P, editors. Coronaviruses: Methods and Protocols. New York, NY: Springer New York; 2015. p. 1–23.
2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579:270–3.
3. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* [Internet]. 2020; Available from: <http://dx.doi.org/10.1056/NEJMoa2002032>

4. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. *J Autoimmun.* 2020;102434.
5. Roser M, Ritchie H, Ortiz-Ospina E. Coronavirus Disease (COVID-19) – Statistics and Research. *Our World in Data* [Internet]. 2020 [cited 2020 Mar 17]; Available from: <https://ourworldindata.org/coronavirus>
6. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. *Euro Surveill* [Internet]. 2020;25. Available from: <http://dx.doi.org/10.2807/1560-7917.ES.2020.25.5.2000062>
7. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* [Internet]. American Association for the Advancement of Science; 2020 [cited 2020 Mar 16]; Available from: <https://science.sciencemag.org/content/early/2020/03/13/science.abb3221.full>
8. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* [Internet]. 2020; Available from: [http://dx.doi.org/10.1016/S1473-3099\(20\)30086-4](http://dx.doi.org/10.1016/S1473-3099(20)30086-4)
9. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,

retrospective, observational study. *Lancet Respir Med* [Internet]. 2020; Available from:  
[http://dx.doi.org/10.1016/S2213-2600\(20\)30079-5](http://dx.doi.org/10.1016/S2213-2600(20)30079-5)

10. Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. *Lancet* [Internet]. Elsevier; 2020; Available from:  
[https://doi.org/10.1016/S0140-6736\(20\)30607-3](https://doi.org/10.1016/S0140-6736(20)30607-3)

11. Harcourt J, Tamin A, Lu X, Kamili S, Sakhivel SK, Murray J, et al. Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient [Internet]. *bioRxiv*. 2020 [cited 2020 Mar 16]. p. 2020.03.02.972935. Available from:  
<https://www.biorxiv.org/content/10.1101/2020.03.02.972935v2>

12. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Hu Y, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China [Internet]. *bioRxiv*. 2020 [cited 2020 Mar 16]. p. 2020.01.24.919183. Available from: <https://www.biorxiv.org/content/10.1101/2020.01.24.919183v2>

13. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395:565–74.

14. Kim D, Lee J-Y, Yang J-S, Kim JW, Narry Kim V, Chang H. The architecture of SARS-CoV-2 transcriptome [Internet]. *bioRxiv*. 2020 [cited 2020 Mar 14]. p. 2020.03.12.988865. Available from:  
<https://www.biorxiv.org/content/10.1101/2020.03.12.988865v1>

15. Ahmed SF, Quadeer AA, McKay MR. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. *Viruses* [Internet]. 2020;12. Available from: <http://dx.doi.org/10.3390/v12030254>
16. Feng Y, Qiu M, Zou S, Li Y, Luo K, Chen R, et al. Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2) [Internet]. *bioRxiv*. 2020 [cited 2020 Mar 16]. p. 2020.03.03.962332. Available from: <https://www.biorxiv.org/content/10.1101/2020.03.03.962332v1>
17. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender differences in patients with COVID-19: Focus on severity and mortality. *medRxiv*. Cold Spring Harbor Laboratory Press; 2020;2020.02.23.20026864.
18. Jansen A, Chiew M, Konings F, Lee C-K, Ailan L, on behalf the World Health Organization Regional Office for the Western Pacific MERS Event Management Team. Sex matters - a preliminary analysis of Middle East respiratory syndrome in the Republic of Korea, 2015. *Western Pac Surveill Response J*. 2015;6:68–71.
19. Karlberg J, Chong DSY, Lai WYY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? *Am J Epidemiol*. 2004;159:229–31.
20. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *J Immunol*. 2017;198:4046–53.

21. Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med* [Internet]. 2020; Available from: [http://dx.doi.org/10.1016/S2213-2600\(20\)30117-X](http://dx.doi.org/10.1016/S2213-2600(20)30117-X)
22. Jaimes JA, Andre NM, Millet JK, Whittaker GR. Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses [Internet]. *arXiv [q-bio.BM]*. 2020. Available from: <http://arxiv.org/abs/2002.06196>
23. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol* [Internet]. 2020; Available from: <http://dx.doi.org/10.1128/JVI.00127-20>
24. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. *Proc Natl Acad Sci U S A*. 2005;102:7988–93.
25. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ Res*. 2000;87:E1-9.
26. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*. 2004;203:631–7.

27. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. *FEBS Lett.* 2002;532:107–10.
28. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov [Internet]. *bioRxiv.* 2020 [cited 2020 Mar 16]. p. 2020.01.26.919985. Available from: <https://www.biorxiv.org/content/10.1101/2020.01.26.919985v1>
29. Sungnak W, Huang N, Bécavin C, Berg M, HCA Lung Biological Network. SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways [Internet]. *arXiv [q-bio.CB].* 2020. Available from: <http://arxiv.org/abs/2003.06122>
30. Cai G. Bulk and Single-Cell Transcriptomics Identify Tobacco-Use Disparity in Lung Gene Expression of ACE2, the Receptor of 2019-nCov [Internet]. *LIFE SCIENCES.* 2020. Available from: <https://www.preprints.org/manuscript/202002.0051/v2>
31. Zill P, Baghai TC, Schüle C, Born C, Früstück C, Büttner A, et al. DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression. *PLoS One.* 2012;7:e40479.
32. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. *J Biol Chem.* 2000;275:33238–43.

33. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nat Commun.* 2018;9:5068.
34. Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. *Bioinformatics.* 2017;33:3982–4.
35. Sundar IK, Yin Q, Baier BS, Yan L, Mazur W, Li D, et al. DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD. *Clin Epigenetics.* 2017;9:38.
36. Cotton AM, Price EM, Jones MJ, Balaton BP, Kobor MS, Brown CJ. Landscape of DNA methylation on the X chromosome reflects CpG density, functional chromatin state and X-chromosome inactivation. *Hum Mol Genet.* 2015;24:1528–39.
37. Shi J, Marconett CN, Duan J, Hyland PL, Li P, Wang Z, et al. Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue. *Nat Commun.* 2014;5:3365.
38. White MC, Fleeman R, Arnold AC. Sex differences in the metabolic effects of the renin-angiotensin system. *Biol Sex Differ.* 2019;10:31.
39. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-analysis. *Am J Hum Genet.* 2016;98:680–96.

40. Stueve TR, Li W-Q, Shi J, Marconett CN, Zhang T, Yang C, et al. Epigenome-wide analysis of DNA methylation in lung tissue shows concordance with blood studies and identifies tobacco smoke-inducible enhancers. *Hum Mol Genet.* 2017;26:3014–27.
41. Carmona JJ, Barfield RT, Panni T, Nwanaji-Enwerem JC, Just AC, Hutchinson JN, et al. Metastable DNA methylation sites associated with longitudinal lung function decline and aging in humans: an epigenome-wide study in the NAS and KORA cohorts. *Epigenetics.* 2018;13:1039–55.
42. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature.* 2012;489:57–74.
43. Li D, Hsu S, Purushotham D, Sears RL, Wang T. WashU Epigenome Browser update 2019. *Nucleic Acids Res.* 2019;47:W158–65.
44. Turner AJ. Chapter 25 - ACE2 Cell Biology, Regulation, and Physiological Functions. In: Unger T, Steckelings UM, dos Santos RAS, editors. *The Protective Arm of the Renin Angiotensin System (RAS)*. Boston: Academic Press; 2015. p. 185–9.
45. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med* [Internet]. 2020; Available from: [http://dx.doi.org/10.1016/S2213-2600\(20\)30116-8](http://dx.doi.org/10.1016/S2213-2600(20)30116-8)
46. Hiremath S. The Coronavirus Conundrum: ACE2 and Hypertension Edition — NephJC [Internet]. *NephJC*. NephJC; 2020 [cited 2020 Mar 16]. Available from: <http://www.nephjc.com/news/covidace2>

47. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res [Internet]. 2020; Available from: <http://dx.doi.org/10.1002/ddr.21656>

48. Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Einfeld AJ, Walters KB, et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci U S A. 2018;115:E1012–21.

49. Davis CA, Hitz BC, Sloan CA, Chan ET, Davidson JM, Gabdank I, et al. The Encyclopedia of DNA elements (ENCODE): data portal update. Nucleic Acids Res. 2018;46:D794–801.